Last reviewed · How we verify
HX575 epoetin alfa
HX575 is a biosimilar epoetin alfa that stimulates erythropoiesis by binding to and activating the erythropoietin receptor on bone marrow progenitor cells.
HX575 is a biosimilar epoetin alfa that stimulates erythropoiesis by binding to and activating the erythropoietin receptor on bone marrow progenitor cells. Used for Anemia of chronic kidney disease, Chemotherapy-induced anemia, Anemia in patients with cancer.
At a glance
| Generic name | HX575 epoetin alfa |
|---|---|
| Also known as | Binocrit® (Europe), Epoetin alfa HEXAL® (Europe), Abseamed® (Europe) |
| Sponsor | Sandoz |
| Drug class | Erythropoiesis-stimulating agent (ESA) / Biosimilar |
| Target | Erythropoietin receptor (EPOR) |
| Modality | Small molecule |
| Therapeutic area | Hematology / Oncology |
| Phase | Phase 3 |
Mechanism of action
Epoetin alfa is a recombinant human erythropoietin that mimics the natural hormone responsible for red blood cell production. By activating erythropoietin receptors on erythroid progenitor cells in the bone marrow, it promotes proliferation and differentiation, increasing hemoglobin and hematocrit levels. HX575 is a biosimilar formulation designed to have equivalent efficacy and safety to the reference epoetin alfa product.
Approved indications
- Anemia of chronic kidney disease
- Chemotherapy-induced anemia
- Anemia in patients with cancer
Common side effects
- Hypertension
- Thrombotic events (venous thromboembolism, stroke)
- Headache
- Injection site reactions
- Pure red cell aplasia (rare)
Key clinical trials
- A Trial Comparing Three Different Treatment Options for Adults With Low-Risk Myelodysplasia and Anemia (A MyeloMATCH Treatment Trial) (PHASE2)
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) (PHASE2)
- Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia (PHASE3)
- ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions (PHASE3)
- Vafseo Outcomes In-Center Experience (PHASE3)
- A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions (PHASE3)
- Choices About Genetic Testing And Learning Your Risk With Smart Technology (NA)
- Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HX575 epoetin alfa CI brief — competitive landscape report
- HX575 epoetin alfa updates RSS · CI watch RSS
- Sandoz portfolio CI